September 3, 2024
On Friday, August 9, 2024, Teikyo University signed an exclusive license agreement with QIX Corporation (Morino, Machida, Tokyo; hereinafter referred to as "QIX") for the development and sale of animal products using an invention regarding the natural ingredient citral, for which the university is currently applying for a patent.
Teikyo University Institute of Medical Mycology Professor The research team led by Rui Kano and his colleagues and veterinarian Nobuo Murayama of Dogs & Cats , which is operated by Dobutsu no (Hirano, Koto-ku, Tokyo), have confirmed that the natural ingredient citral has preventive and therapeutic effects against Malassezia pachydermatis, the bacterium that causes Malassezia Dermatology Dermatology dermatitis* in dogs. The University and the company have confirmed that it is effective in preventing and treating canine Malassezia pachydermatis. The University and the company have filed a patent application together for a composition for the prevention or treatment of Malassezia pachydermatis and a method for the prevention or treatment of Malassezia pachydermatis in animals (Patent Application 2024-133762). Under this agreement, QIX will develop and market animal skin care products using the antifungal and antibacterial effects of Citral, and contribute to the treatment and prevention of canine Malassezia dermatitis in veterinary clinics in cooperation with TMDU.
For more information about the Medical Mycology Research Center, click here
For more information about Professor Kano, click here
For more information about QIX Corporation, click here